We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Haleon Plc | LSE:HLN | London | Ordinary Share | GB00BMX86B70 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 329.60 | 330.20 | 330.30 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 11.3B | 1.05B | 0.1136 | 29.08 | 30.5B |
From Apr 2023 to Apr 2024
By Ian Walker
GSK said Friday that it has now sold 240 million shares in consumer healthcare business Haleon for 335 pence each, raising 804 million pounds ($1.01 billion), as first announced late Thursday.
The pharmaceutical giant said Thursday night that it was selling the shares via an accelerated bookbuild. The sale price is a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday.
Following the sale GSK will continue to hold 955 million Haleon shares, or 10.3% of its issued share capital.
Haleon--which includes well-known brands such as Sensodyne and Voltaren--was formed in July 2019 between GSK and Pfizer via the merger of their consumer healthcare businesses into a new joint-venture company.
It was spun out and listed on the London Stock Exchange last July. Pfizer has a 32% shareholding in Haleon.
GSK and Pfizer have agreed not to sell any further Haleon shares for 60 days.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 12, 2023 02:32 ET (06:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Haleon Chart |
1 Month Haleon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
